Genomic Medicine at Fortis Memorial Research Institute, Gurgaon

Molecular Hematology & Oncology is a cutting-edge specialty at the intersection of cancer biology, hematology, and precision medicine. By integrating advanced genomic technologies with clinical expertise, we diagnose, classify, and guide treatment for blood cancers and solid tumors with unmatched accuracy. At Fortis, our dedicated team of molecular oncologists, pathologists, and geneticists work together to deliver individualized, research-driven care.

Conditions We Address

Leukemias (AML, ALL, CML, CLL)
Lymphomas (DLBCL, Hodgkin lymphoma, T-cell lymphomas, etc.)
Multiple Myeloma & Plasma Cell Disorders
Myelodysplastic & Myeloproliferative Neoplasms
Inherited Bone Marrow Failure Syndromes & Familial Leukemia
Solid Tumors with Hematology Overlap (lung, breast, sarcomas, pediatric cancers)

Future-Ready Genomics

The Fortis Molecular Hematology & Oncology program is building India’s most advanced genomic registries, AI-powered interpretation platforms, and translational research pipelines to bring tomorrow’s medicine to today’s patients.

 “Every cancer is unique. At Fortis, our molecular insights ensure that every treatment is, too.”

 

 

Key USPs

  • Real-time NGS

    Delivers same-day genomic results for timely treatment decisions.

  • AI-powered analytics

    Enhances speed and precision of data interpretation.

  • Research leadership

    Advances India’s genomic medicine through clinical registries.

  • Fortis-Agilus backing

    Strong infrastructure and wide accessibility across India.

  • Expert in-house team

    Provides clinical and genomic integration internally

  • Broad genomic specialties

    Covers oncology, cardiology, and neurology under one roof.

  • Why Molecular Diagnostics Matter

    Earlier & Accurate Diagnosis – Genetic and molecular profiling helps identify cancers at their earliest stages.

    Precise Classification – Goes beyond conventional pathology to define molecular subtypes of leukemia, lymphoma, and myeloma.

    Personalized Treatment – Links genetic alterations with FDA-approved therapies, NCCN/ESMO guidelines, and clinical trial opportunities.

    Prognostication & Monitoring – Tracks measurable residual disease (MRD), therapy response, and risk of relapse.

    Familial & Inherited Risk Detection – Identifies cancer predisposition syndromes for patients and families.

  • Services We Offer

    Next-Generation Sequencing (NGS) Panels

    Comprehensive DNA & RNA profiling for leukemias, lymphomas, myeloma, and solid tumors.

    Rapid turnaround with real-time NGS (Ion Torrent Genexus).

    Minimal Residual Disease (MRD) Testing

    Ultra-sensitive detection of residual leukemia/myeloma cells post-therapy.

    Cytogenetics & Molecular Cytogenomics

    Karyotyping, FISH, and low-pass whole-genome sequencing to detect chromosomal abnormalities.

    Hereditary Cancer Testing

    Panels for familial leukemia syndromes, BRCA-associated cancers, and other inherited conditions.

    Genomic Tumor Boards

    Multidisciplinary review of complex cases with oncologists, hematologists, geneticists, and pathologists.

    Targeted Therapy & Clinical Trial Mapping

    Reports integrated with global databases (OncoKB, CIViC, JAX CKB) to guide personalized therapy.

    Genetic Counseling & Patient Education

    Expert counseling for patients and families to understand and act on genomic findings.

     

  • Our Strengths

    Fastest TAT in India – Real-time NGS with reports in days, not weeks.

    Global Standard Reporting – AMP/ASCO/CAP/ACMG guideline-based.

    Integrated Multi-disciplinary Care – Works hand-in-hand with hematologists, oncologists, and transplant teams.

    AI-powered Analytics – Intelligent reporting pipelines for rapid and reliable interpretation.

    Research Leadership – National registries, prospective studies, and pioneering work in CHIP, AML, lymphoma, and transplant genomics.


    Future-Ready Genomics

    The Fortis Molecular Hematology & Oncology program is building India’s most advanced genomic registries, AI-powered interpretation platforms, and translational research pipelines to bring tomorrow’s medicine to today’s patients.

    🔹 “Every cancer is unique. At Fortis, our molecular insights ensure that every treatment is, too.”

     

Our Team of Experts

View all

Our Speciality

  • Thumbnail

    Medical Genetics

Other Hospitals

FAQs

  • Why Choose Us

    • Fastest TAT in India – Reports in days, not weeks.
    • Internationally benchmarked reporting (AMP/ASCO/CAP/ACMG).
    • Seamless integration with hematology/oncology clinical care.
    • National research leadership in AML, CHIP, MRD, DLBCL, and immune-oncology genomics.
    • Pioneers of real-time NGS in India.

Request a Callback

Request callback